Newsletter Subject

Ensysce Biosciences Inc. (NASDAQ: ENSC): This Sub-Dollar Stock Is Making A Huge Impact To Cure The Opioid Crisis

From

10xprotrader.com

Email Address

newsletter@10xprotrader.com

Sent On

Mon, May 20, 2024 11:02 AM

Email Preheader Text

This Sub-dollar Stock Is Making A Huge Impact To Cure The Opioid Crisis [Ensysce Biosciences ] 10XPr

This Sub-dollar Stock Is Making A Huge Impact To Cure The Opioid Crisis [Ensysce Biosciences (NASDAQ: ENSC)]( 10XProTrader Member, Hello Kevin Vander here delivering you your new premium alert for Today's 5/20 trading session which is [Ensysce Biosciences Inc. (NASDAQ: ENSC),]( a company making huge strides to combat the opioid crisis. Folks, while the headline flavor of the day may not be about the opioid crisis, make no mistake- it's still a major national crisis. As investors, it's no longer the time to place blame. Instead, it's time to seize investment opportunities in companies focused on curing the issue, not contributing to it. And right now, that's not Big Pharma. While many of them may present a conciliatory narrative for the reporters, they for sure don't want to walk away from the billions in profits made yearly from opioid prescriptions. In other words, investors who want to be on the right side of this trade should seize the investment opportunities presented by companies that provide tangible solutions. [NASDAQ-listed Ensysce Biosciences (NASDAQ: ENSC) is one to put on your shortlist for consideration and, more directly, action.]( A Lethal Weapon In The Battle Against Opioid Abuse And Overdose Why? Because companies, like Ensysce Biosciences, that can help to effectively mitigate the devastating consequences of opioid abuse stand to earn billions. That's not an exaggeration, either. Not only is the U.S. starved for answers on how to curb the abuse, but many other countries are as well. And the amount of money they are willing to pay to eradicate opioid abuse can be nearly limitless into the end of this decade. Call it a full-court pressure, with funds front-loaded, to end this crisis sooner rather than later. That can play directly into Ensysce Biosciences' waiting marketing hands and bank accounts. Look, at $0.62 a share at Friday's close, an investor might think this company is too small to have an impact. I get it, some think small can't compete. However, in the biotech world, small companies can become large on a single headline. Fortunes are literally made overnight by investors being rewarded for investing foresight ahead of a new drug or treatment approval. So, no—Ensynsce Biosciences isn't too small for anything. In fact, it is priced and positioned to yield potentially exponential increases in company size and share value. That trend is underway. The company's stock surged over 21% since May 10th as more investors realize that it is on the path to offering some of the most innovative, abuse-resistant opioid solutions that promise to revolutionize pain management. [FDA Grants Breakthrough Therapy Designation]( [The company's Breakthrough Technologies, its flagship PF614, and PF614-MPAR, are expected to be absolute game-changers in the pain relief market.]( are so potentially potent that the FDA granted PF614-MPAR Breakthrough Therapy designation, recognizing its potential to significantly improve severe pain management with built-in overdose protection. If you don't think that's a big deal, consider this: Since its inception, the Breakthrough Therapy designation has been awarded to fewer than 300 drugs. So, earning its way on that list is more than impressive; it's valuable from an investor's perspective because it accelerates the development and review process and, perhaps more importantly, can attract deep-pocketed Big Pharma interest. Remember, despite Big Pharma having ushered in the crisis, many now see their path to redemption is to help cure it. As contradictory as it may sound to their own profit motives, it's not. If Big Pharma can provide or partner with a company delivering to the market an abuse-deterrent drug with the same sales potential, that can be the most profitable win-win proposition ever created. Of course, the alternative must be effective. Ensynsce Biosciences' checks that box. Its PF614 is developed using the [Trypsin-Activated Abuse Protection (TAAP™) technology]( to provide the same pain relief as traditional opioids like oxycodone but with extended-release and abuse-resistant properties. [Phase 3 clinical trials for PF614 are planned to start in the back half of this year.]( Here's even better news: The FDA's constructive feedback and guidelines for these trials have provided a clear roadmap toward earning approval, significantly reduced regulatory risks, and have helped pave a clear pathway toward commercialization. Ensynsce Biosciences Has Stacked The Deck Those are value cards that few, if any, Ensynsce Biosciences competitors can play. Frankly, most still need a comparable technology deck to even play from. that's what makes the Ensynsce Biosciences candidate different. Its innovative combination of PF614 with the Multi-Pill Abuse Resistance (MPAR®) technology actually prevents overdose through a mechanism that "turns off" the release of oxycodone if more than the prescribed dose is consumed.]( That could save many of the over 107,000 lives lost in 2023. More than saving a human toll, it could help rehabilitate countless individuals, affected families, and communities. Thus,[Ensysce Biosciences']( isn't only a safer opioid alternative from a scientific perspective, it can be a crucial contributor to the humanitarian effort that can provide hope to millions, save billions of dollars that go toward rehab and incarcerations, and, most importantly, provide essential pain relief to those that need it without the fear of government intrusion that tells doctors what and how much medicine to prescribe. Ironically, microcap company[Ensysce Biosciences]( leading the charge in helping win this critical battle against the opioid crisis. And after a successful capital raise and strategic financial management, they appear to have one of the clearest paths toward regulatory approval for a drug that could eclipse blockbuster-level sales (a billion or more) within weeks of commercialization. Phase 3 Valuation Could Send The ENSC Stock Price Soaring Remember, fellow investors, [Ensysce Biosciences]( isn't starting its clinical trial ambitions; [it's about to enter Phase 3](. It's no secret that the difference in valuations of a Phase 3 company compared to a Phase 2 one can be tens or even hundreds of millions. In other words, don't be surprised to wake up to an ENSC share price of 2X, 3X, or even 10X higher. That potential is indee d in play based on what is likely to be massive interest in this company's late-stage drug pipeline. Don't forget- Ensysce Biosciences is guided to start Phase 3 by mid-year, just weeks away. Still, investing in partnership or buyout speculation is the smallest part of the value proposition exposed. Investors should also be focused on the vast revenue-generating potential in this company's crosshairs. Know this: Going on this project alone certainly wouldn't be the worst option. While it may trigger some dilution, the windfall upon commercialization would most likely dwarf that cost. Thus, with[Ensysce Biosciences]( charging toward a Phase 3 trial with proprietary next-gen drug development platforms, its stock at current prices may present more than a bargain; it may be as ground floor as it gets. And with expected milestones in the queue that could immediately steepen the share price curve, re-claiming its 52-week high of $2.84, 350% higher than its current price, could be a near-term target already in the crosshairs. Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.

Marketing emails from 10xprotrader.com

View More
Sent On

06/06/2024

Sent On

06/06/2024

Sent On

06/06/2024

Sent On

06/06/2024

Sent On

05/06/2024

Sent On

29/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.